# Program 1 Architecture Review Track Phase C7 - Write-Back and Mutation Prohibition Trace

Status: documentation-only prohibited write-back trace.

| Prohibited path | Risk | Current decision | Future review dependency |
| --- | --- | --- | --- |
| Synthetic recommendation -> real patient instruction | Patient communication and treatment execution risk | Prohibited | Clinical safety, patient communication, and implementation authorization |
| Synthetic finding -> clinical note | Clinical write-path risk | Prohibited | Clinical accountability and implementation authorization |
| Synthetic review -> diagnosis entry | Autonomous or unsupported diagnosis risk | Prohibited | Clinical safety and accountability review |
| Synthetic review -> treatment execution | Treatment automation risk | Prohibited | Clinical safety and accountability review |
| Synthetic appointment placeholder -> appointment mutation | Scheduling mutation risk | Prohibited | Appointment governance review |
| Synthetic message placeholder -> patient message | Patient communication risk | Prohibited | Patient communication governance review |
| Synthetic task placeholder -> task assignment | Task engine/workflow risk | Prohibited | Workflow governance review |
| Synthetic outcome placeholder -> Outcome Evidence creation | Outcome Evidence activation risk | Prohibited | Outcome governance review |
| Synthetic authorization concept -> runtime access grant | Runtime authz risk | Prohibited | Security architecture review |
| Synthetic audit concept -> runtime audit event capture | Runtime audit behavior risk | Prohibited | Audit/security architecture review |
| Blocker status -> approval/override capability | Clearance or override semantics risk | Prohibited | Governance authorization; no automatic approval |

## Decision

Phase C prohibits all write-back and mutation paths. No clinical write behavior, patient instruction, appointment mutation, task assignment, Outcome Evidence creation, runtime access grant, runtime audit capture, approval/clearance/override capability, production use, or go-live is authorized.
